V1RE11 Inhibitors
V1RE11 inhibitors belong to a specialized class of chemical compounds that target a specific protein or enzyme function within biological systems. The name of this class typically follows a convention where the target is encoded within the nomenclature; in this case, V1RE11 refers to the particular molecular structure or pathway these inhibitors are designed to interact with. The inhibitors work by binding to the active site or another crucial part of the target molecule, thereby hindering its natural function. This action is akin to inserting a key into a lock but not turning it, effectively blocking the lock from being used by the correct key. The precise mechanism of action can vary within the class, ranging from competitive inhibition-where the inhibitor competes with the natural substrate for binding sites-to non-competitive inhibition, where the inhibitor binds to a different site and induces conformational changes that reduce the activity of the target molecule.
The development of V1RE11 inhibitors is a complex process that requires a deep understanding of the target's structure and the dynamics of its interaction with potential inhibitors. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling are often employed to elucidate the three-dimensional configuration of the target and to screen for potential binding compounds. Once identified, these compounds undergo extensive modification and optimization to enhance their binding affinity, selectivity, and stability within a biological context. The focus lies on achieving a high degree of specificity, as off-target effects can lead to unintended interactions with other molecular pathways. The chemical properties of V1RE11 inhibitors, such as solubility, reactivity, and metabolic stability, are fine-tuned to ensure that they can reach and effectively interact with their target within the complex milieu of a biological system. The synthesis of such compounds is a meticulous task, often requiring multi-step reactions and careful control of reaction conditions to yield products with the desired purity and isomeric configuration.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and the resulting complex inhibits mTOR, a kinase involved in cell growth and proliferation. When mTOR is inhibited, it can lead to reduced protein synthesis and cellular metabolism, which may decrease V1RE11 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, which is crucial for the activation of AKT signaling pathway. By inhibiting PI3K, AKT phosphorylation and subsequent activation are reduced, potentially diminishing the functional activity of V1RE11. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 selectively inhibits MEK1, which in turn prevents the activation of ERK1/2 MAPKs. This inhibition may affect downstream signaling events that could regulate the activity of V1RE11 through transcriptional or post-translational modifications. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2 which are upstream regulators of ERK1/2 MAPKs. Inhibition of this pathway can lead to alteration in cell cycle progression and gene expression that may indirectly affect the activity of V1RE11. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The p38 MAPK pathway is involved in stress responses and inflammation. Inhibiting p38 MAPK can alter cellular responses to stress and cytokines, potentially decreasing the activity of V1RE11. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK family that regulates apoptosis, cell proliferation, and cytokine production. Inhibition of JNK signaling could lead to changes in these cellular processes that might inhibit V1RE11 function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the proliferation and survival of certain cell types. This could lead to a reduction in pathways that are potentially regulating V1RE11 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets multiple receptors including RAF, VEGFR, and PDGFR. By inhibiting these pathways, it may decrease signaling events that lead to the activation of V1RE11. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor which interferes with chromosome alignment and segregation during mitosis. Disruption of mitotic events could indirectly decrease the functional activity of V1RE11. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that impedes the degradation of protein substrates, affecting cellular homeostasis and signaling. This can lead to a buildup of proteins that may negatively regulate the activity of V1RE11. | ||||||